Early oncology studies are not smaller versions of late-phase trials. They are exploratory environments where teams build knowledge patient by patient and must be comfortable making decisions before certainty exists.

Early oncology development is full of unknowns, and the greatest risks are not always the ones already on the checklist. Strong teams learn to look for what the study may not yet be showing them.

A dose-limiting toxicity is more than a protocol checkbox. DLT adjudication requires clinical context, pattern recognition, and judgment because one decision can shape the direction of an entire development program.

Medical monitoring is most valuable before a safety signal becomes obvious. This launch issue explores why early recognition, clinical judgment, and proactive oversight matter in early development.